StockNow
Calendar
Log in
U.S. MarketsIMPORTANT

Johnson & Johnson (JNJ) Q3 2026 (USD): Adj. EPS 2.59 (exp. 2.67), Revenue 25.4bln (exp. 25.38bln), sees FY26 Adj. EPS between 11.05-11.15 (prev. 10.96-11.11) and Revenue 101-101.4 (prev. 100.8-101.4bln)

StockNow breaking-news AI analysis

Johnson & Johnson’s Q3 2026 release reports adjusted EPS below expectations, revenue slightly above expectations, updated FY2026 guidance, a one-time special charge, and a CFO preference for a possible orthopaedic spinoff.

News detail

Reflects a one-time special charge for the proposed talc litigation resolution, the acquisition of Firefly Bio, and the strategic collaboration with Sail Biomedicines. CFO says they are leaning toward Orthopaedic Unit spinoff instead of sale.

1 stocks
JNJJohnson & Johnson$257.20Current price

What do investors think?

Curious what other investors think?Log in to see reactions and join the conversation.
Log in to view reactions

StockNow uses AI to translate and analyze information and does not guarantee its accuracy or completeness.

Today's market highlights

A selection of stories drawing attention in the market.

See more
U.S. Markets

UnitedHealth Group (UNH) Q3 2026 (USD): Adj. EPS 4.69 (exp. 4.12), Revenue 112.7bln (exp. 111.31bln). Sees FY Adj. EPS "at least" 20.50 (exp. 19.80)

UNHGeopolitics

Iran and the US remain divided over the sequencing of a diplomatic agreement, Al-Akhbar reports via Kan

Fed

Fed's Waller (Voter, Dovish) says the US remains the dominant country in building AI models and AI could contribute to widening GDP per capita